Top

BMC Psychiatry

Published in:

01-12-2021 | Mood Disorders | Research

Anhedonia difference between major depressive disorder and bipolar disorder II

Authors: Xinyu Fang, Dandan Wang, Wei Tang, Hongyang Liu, Xiangrong Zhang, Chen Zhang

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Objective

This study aims to explore the difference in anhedonia between Major Depressive Disorder (MDD) and Bipolar Disorder II (BD-II), and attempt to distinguish the two diseases through Snaith-Hamilton Pleasure Scale (SHAPS).

Methods

A total of 164 drug-free depressive patients (98 MDD patients, 66 BD-II patients) completed the investigation. 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA) and SHAPS were assessed in all participants.

Results

Our results showed that BD-II patients had higher SHAPS scores than MDD patients. The stepwise logistic regression analysis further revealed that SHAPS score, drinking habit, and extroversion as influencing factors for the identification of BD-II. The ROC curve analysis indicated that SHAPS could differentiate BD-II from MDD patients (AUC = 0.655, P = 0.001, 95% CI = 0.568 to 0.742), with the best screening cutoff at 26, and the corresponding sensitivity and specificity was 0.788 and 0.520, respectively.

Conclusion

Our results suggest that BD-II patients had more severe anhedonia compared to MDD patients, and the difference in anhedonia may help clinicians preliminary identify BD patients from MDD patients. The preliminary findings are worthly of further exploration.

Available only for authorised users

Zhang C, Rong H. Genetic advance in depressive disorder. Adv Exp Med Biol. 2019;1180:19–57. https://doi.org/10.1007/978-981-32-9271-0_2.CrossRefPubMed

Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, et al. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. J Manag Care Spec Pharm. 2020;37(1):1–12. https://doi.org/10.1080/03007995.2020.1844645.CrossRef

Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–41. https://doi.org/10.1001/jamapsychiatry.2014.2502.CrossRefPubMedPubMedCentral

Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–24. https://doi.org/10.1016/S2215-0366(18)30511-X.CrossRefPubMed

Zheng Y, He S, Zhang T, Lin Z, Shi S, Fang Y, et al. Detection study of bipolar depression through the application of a model-based algorithm in terms of clinical feature and peripheral biomarkers. Front Psychiatry. 2019;10:266. https://doi.org/10.3389/fpsyt.2019.00266.CrossRefPubMedPubMedCentral

Rive MM, Redlich R, Schmaal L, Marquand AF, Dannlowski U, Grotegerd D, et al. Distinguishing medication-free subjects with unipolar disorder from subjects with bipolar disorder: state matters. Bipolar Disord. 2016;18(7):612–23. https://doi.org/10.1111/bdi.12446.CrossRefPubMed

Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161–74. https://doi.org/10.4088/JCP.v64n0209.CrossRefPubMed

Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and manic-depressive association (DMDA) survey of bipolar members. J Affect Disord. 1994;31(4):281–94. https://doi.org/10.1016/0165-0327(94)90104-X.CrossRefPubMed

Zheng P, Yang J, Li Y, Wu J, Liang W, Yin B, et al. Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2020;7(7):1902862.

10.

Perlis RH. Misdiagnosis of bipolar disorder. Am J Manag Care. 2005;11(9 Suppl):S271–4.PubMed

11.

Schosser A, Gaysina D, Cohen-Woods S, Chow PC, Martucci L, Craddock N, et al. Association of DISC1 and TSNAX genes and affective disorders in the depression case-control (DeCC) and bipolar affective case-control (BACCS) studies. Mol Psychiatry. 2010;15(8):844–9. https://doi.org/10.1038/mp.2009.21.CrossRefPubMed

12.

Liebers DT, Pirooznia M, Ganna A, Goes FS. Discriminating bipolar depression from major depressive disorder with polygenic risk scores. Psychol Med. 2020;51(9):1–8. https://doi.org/10.1017/S003329172000015X.CrossRef

13.

Mao R, Zhang C, Chen J, Zhao G, Zhou R, Wang F, et al. Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression. J Affect Disord. 2018;237:65–72. https://doi.org/10.1016/j.jad.2018.04.115.CrossRefPubMed

14.

Ren J, Zhao G, Sun X, Liu H, Jiang P, Chen J, et al. Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis. Psychoneuroendocrinology. 2017;86:17–24. https://doi.org/10.1016/j.psyneuen.2017.09.005.CrossRefPubMed

15.

Zhao G, Zhang C, Chen J, Su Y, Zhou R, Wang F, et al. Ratio of mBDNF to proBDNF for differential diagnosis of major depressive disorder and bipolar depression. Mol Neurobiol. 2017;54(7):5573–82. https://doi.org/10.1007/s12035-016-0098-6.CrossRefPubMed

16.

Alamian G, Hincapié AS, Combrisson E, Thiery T, Martel V, Althukov D, et al. Alterations of intrinsic brain connectivity patterns in depression and bipolar disorders: a critical assessment of Magnetoencephalography-based evidence. Front Psychiatry. 2017;8:41. https://doi.org/10.3389/fpsyt.2017.00041.CrossRefPubMedPubMedCentral

17.

Yang HC, Liu TB, Rong H, Bi JQ, Ji EN, Peng HJ, et al. Evaluation of mood disorder questionnaire (MDQ) in patients with mood disorders: a multicenter trial across China. PLoS One. 2014;9(4):e91895. https://doi.org/10.1371/journal.pone.0091895.CrossRefPubMedPubMedCentral

18.

Hung CI, Liu CY, Yang CH. Persistent depressive disorder has long-term negative impacts on depression, anxiety, and somatic symptoms at 10-year follow-up among patients with major depressive disorder. J Affect Disord. 2019;243:255–61. https://doi.org/10.1016/j.jad.2018.09.068.CrossRefPubMed

19.

Sun DL, Liu QH, Li MJ, Yang Y, Zhang R, Li M, et al. Patient health questionnaire-15 (PHQ-15) to distinguish bipolar II disorder from major depressive disorder. Psychiatry Res. 2020;290:113026. https://doi.org/10.1016/j.psychres.2020.113026.CrossRefPubMed

20.

Alloy LB, Olino T, Freed RD, Nusslock R. Role of reward sensitivity and processing in major depressive and bipolar Spectrum disorders. Behav Ther. 2016;47(5):600–21. https://doi.org/10.1016/j.beth.2016.02.014.CrossRefPubMedPubMedCentral

21.

Whitton AE, Treadway MT, Pizzagalli DA. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry. 2015;28(1):7–12. https://doi.org/10.1097/YCO.0000000000000122.CrossRefPubMedPubMedCentral

22.

Han S, Cui Q, Wang X, Chen Y, Li D, Li L, et al. The anhedonia is differently modulated by structural covariance network of NAc in bipolar disorder and major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2020;99:109865. https://doi.org/10.1016/j.pnpbp.2020.109865.CrossRef

23.

Liu WH, Wang LZ, Zhu YH, Li MH, Chan RC. Clinical utility of the Snaith-Hamilton-pleasure scale in the Chinese settings. BMC Psychiatry. 2012;12(1):184. https://doi.org/10.1186/1471-244X-12-184.CrossRefPubMedPubMedCentral

24.

Tang W, Liu H, Chen L, Zhao K, Zhang Y, Zheng K, et al. Inflammatory cytokines, complement factor H and anhedonia in drug-naïve major depressive disorder. Brain Behav Immun. 2021;95:238–44. https://doi.org/10.1016/j.bbi.2021.03.022.CrossRefPubMed

25.

Wu C, Lu J, Lu S, Huang M, Xu Y. Increased ratio of mature BDNF to precursor-BDNF in patients with major depressive disorder with severe anhedonia. J Psychiatr Res. 2020;126:92–7. https://doi.org/10.1016/j.jpsychires.2020.05.010.CrossRefPubMed

26.

Zhang W, Liao C, Tang F, Liu S, Chen J, Zheng L, et al. Emotional contexts modulate anticipatory late positive component and reward feedback negativity in adolescents with major depressive disorder. Front Psychiatry. 2020;11:358. https://doi.org/10.3389/fpsyt.2020.00358.CrossRefPubMedPubMedCentral

27.

He Z, Lu F, Sheng W, Han S, Pang Y, Chen Y, et al. Abnormal functional connectivity as neural biological substrate of trait and state characteristics in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2020;102:109949. https://doi.org/10.1016/j.pnpbp.2020.109949.CrossRef

28.

Yang X, Wang D, Liu S, Liu G, Harrison P. Trajectories of state anhedonia and recent changes in anhedonia in college students: associations with other psychiatric syndromes. J Affect Disord. 2020;262:337–43. https://doi.org/10.1016/j.jad.2019.11.043.CrossRefPubMed

29.

Borsini A, Wallis ASJ, Zunszain P, Pariante CM, Kempton MJ. Characterizing anhedonia: A systematic review of neuroimaging across the subtypes of reward processing deficits in depression. Cogn Affect Behav Neurosci. 2020;20(4):816–41.CrossRefPubMedPubMedCentral

30.

Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, et al. The efficacy of Vortioxetine on Anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17. https://doi.org/10.3389/fpsyt.2019.00017.CrossRefPubMedPubMedCentral

31.

Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4(10):e469. https://doi.org/10.1038/tp.2014.105.CrossRefPubMedPubMedCentral

32.

Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients. Psychiatry Res. 2009;165(1–2):193–6. https://doi.org/10.1016/j.psychres.2008.05.003.CrossRefPubMed

33.

Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton pleasure scale (SHAPS). J Affect Disord. 2007;99(1–3):83–9. https://doi.org/10.1016/j.jad.2006.08.020.CrossRefPubMed

34.

Gosek P, Heitzman J, Stefanowski B, Antosik-Wójcińska AZ, Parnowski T. Symptomatic differences and symptoms stability in unipolar and bipolar depression. Medical charts review in 99 inpatients. Psychiatr Pol. 2019;53(3):655–72. https://doi.org/10.12740/PP/102656.CrossRefPubMed

35.

Souery D, Zaninotto L, Calati R, Linotte S, Mendlewicz J, Sentissi O, et al. Depression across mood disorders: review and analysis in a clinical sample. Compr Psychiatry. 2012;53(1):24–38. https://doi.org/10.1016/j.comppsych.2011.01.010.CrossRefPubMed

36.

Manelis A, Almeida JR, Stiffler R, Lockovich JC, Aslam HA, Phillips ML. Anticipation-related brain connectivity in bipolar and unipolar depression: a graph theory approach. Brain. 2016;139(Pt 9):2554–66. https://doi.org/10.1093/brain/aww157.CrossRefPubMedPubMedCentral

37.

Redlich R, Dohm K, Grotegerd D, Opel N, Zwitserlood P, Heindel W, et al. Reward processing in unipolar and bipolar depression: a functional MRI study. Neuropsychopharmacology. 2015;40(11):2623–31. https://doi.org/10.1038/npp.2015.110.CrossRefPubMedPubMedCentral

38.

Lee Y, Subramaniapillai M, Brietzke E, Mansur RB, Ho RC, Yim SJ, et al. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Ther Adv Psychopharmacol. 2018;8(12):337–48. https://doi.org/10.1177/2045125318791944.CrossRefPubMedPubMedCentral

39.

Lee Y, Mansur RB, Brietzke E, Carmona NE, Subramaniapillai M, Pan Z, et al. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain Behav Immun. 2020;88:631–9.CrossRefPubMed

40.

Lamontagne SJ, Melendez SI, Olmstead MC. Investigating dopamine and glucocorticoid systems as underlying mechanisms of anhedonia. Psychopharmacology. 2018;235(11):3103–13. https://doi.org/10.1007/s00213-018-5007-4.CrossRefPubMed

41.

Szczepankiewicz A, Leszczyńska-Rodziewicz A, Pawlak J, Rajewska-Rager A, Dmitrzak-Weglarz M, Wilkosc M, et al. Glucocorticoid receptor polymorphism is associated with major depression and predominance of depression in the course of bipolar disorder. J Affect Disord. 2011;134(1–3):138–44. https://doi.org/10.1016/j.jad.2011.06.020.CrossRefPubMed

42.

Abraham A, Watson S, Young AH. Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders. Indian J Psychiatry. 2003;45(2):5–14.PubMedPubMedCentral

43.

Szczepankiewicz A, Leszczyńska-Rodziewicz A, Pawlak J, Narozna B, Rajewska-Rager A, Wilkosc M, et al. FKBP5 polymorphism is associated with major depression but not with bipolar disorder. J Affect Disord. 2014;164:33–7. https://doi.org/10.1016/j.jad.2014.04.002.CrossRefPubMed

44.

Angst J, Gamma A, Endrass J, Rössler W, Ajdacic-Gross V, Eich D, et al. Is the association of alcohol use disorders with major depressive disorder a consequence of undiagnosed bipolar-II disorder? Eur Arch Psychiatry Clin Neurosci. 2006;256(7):452–7. https://doi.org/10.1007/s00406-006-0673-3.CrossRefPubMed

45.

Silarova B, Giltay EJ, Van Reedt DA, Van Rossum EF, Hoencamp E, Penninx BW, et al. Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls. J Psychosom Res. 2015;78(4):391–8. https://doi.org/10.1016/j.jpsychores.2015.02.010.CrossRefPubMed

46.

Akiskal HS, Kilzieh N, Maser JD, Clayton PJ, Schettler PJ, Traci Shea M, et al. The distinct temperament profiles of bipolar I, bipolar II and unipolar patients. J Affect Disord. 2006;92(1):19–33. https://doi.org/10.1016/j.jad.2005.12.033.CrossRefPubMed

47.

Jylhä P, Mantere O, Melartin T, Suominen K, Vuorilehto M, Arvilommi P, et al. Differences in neuroticism and extraversion between patients with bipolar I or II and general population subjects or major depressive disorder patients. J Affect Disord. 2010;125(1–3):42–52. https://doi.org/10.1016/j.jad.2010.01.068.CrossRefPubMed

Title: Anhedonia difference between major depressive disorder and bipolar disorder II
Authors: Xinyu Fang
Dandan Wang
Wei Tang
Hongyang Liu
Xiangrong Zhang
Chen Zhang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Mood Disorders
Affective Disorder
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03548-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anhedonia difference between major depressive disorder and bipolar disorder II

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

One year follow-up and mediation in cognitive behavioral therapy and acceptance and commitment therapy for adult depression

Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands

Cortical haemodynamic response during the verbal fluency task in patients with bipolar disorder and borderline personality disorder: a preliminary functional near-infrared spectroscopy study

Fear inoculation among snake experts

Regional brain volume predicts response to methylphenidate treatment in individuals with ADHD

Paliperidone induced neutropenia in first episode psychosis: a case report